الهيئة العامة للغذاء والدواء
Saudi Food & Drug Authority

Saudi Public Assessment Report

(Summary Report)

Fylibix®

Type of Application: New Drug Application.

Type of Product: Human Generic Drug.

Active Pharmaceutical Ingredient(s): Dasatinib.

ATC code: L01XE06.

Dosage Form: Film-coated tablet.

Dosage Strength:70 mg.

Pack Size: 60.

Shelf life: 48 months.

Storage Conditions: Store below 30°c.

Reference Product in SA: SPRYCEL®

Marketing Authorization Holder: HEXAL AG.

Manufacturer: REMEDICA.

Registration No.: 2203233406.

Date of Decision: 22/03/2023

Proposed Indications:

Fylibix is indicated for the treatment of adult patients with:

- Newly diagnosed Philadelphia chromosome positive (Ph+) Chronic Myelogenous Leukaemia (CML) in the chronic phase.
- Chronic, Accelerated Or Blast Phase CML with resistance or intolerance to prior therapy including Imatinib Mesilate.
- Ph+ Acute Lymphoblastic Leukaemia (ALL) and Lymphoid Blast CML with resistance or intolerance to prior therapy.

Product Background

This product is considered as a human generic drug, for Saudi regulatory purposes, qualified to follow the SFDA's regular generic registration regulatory pathway

The SFDA approval for Fylibix® is based on a review of the quality, safety and efficacy of the product provided as an e-CTD in accordance with the relevant guidelines, basic product information summarized hereinafter:

Quality information:

- ### Drug Substance

- Dasatinib is a white to off-white crystalline powder freely soluble in Dimethyl sulfoxide, slightly soluble in methanol and 0.1N Hydrochloric acid solution, very slightly soluble in ethanol, practically insoluble in water. Dasatinib does not have any chiral center. Polymorphism has been observed.
- The drug substance is manufactured by a multiple-step chemical synthesis provided with sufficient information regulatory detailed.
- The structure of Dasatinib has been fully elucidated using several spectroscopic techniques.
- The drug substance specification includes relevant tests for proper quality control. The control methods are validated according to international guidelines.
- Appropriate stability data have been presented and justify the established re-test period.

- ### Drug Product

(Fylibix) drug product is available in (three) strengths:

1. (20mg) (film-coated tablet): (White to off-white, biconvex, round film-coated tablet with "20" debossed on one side and plain on the other).
2. (50mg) (film-coated tablet): (White to off-white, biconvex, oval film-coated tablet with "50" debossed on one side and plain on the other).
3. (70mg) (film-coated tablet): (White to off-white, biconvex, round film-coated tablet with "70" debossed on one side and plain on the other)

- Each (film-coated tablet) contains:

1. (20mg) of (Dasatinib).
2. (50mg) of (Dasatinib).
3. (70mg) of (Dasatinib).

- The composition of the drug product is adequately described, qualitatively and quantitatively. Suitable pharmaceutical development data have been provided for the finished product composition and manufacturing process.
- The manufacturing process is described narratively and in sufficient detail, taking into account pharmaceutical development data. Batch manufacturing formulas and in-process controls are included.
- The drug product specification covers appropriate parameters for this dosage form which allow for proper control of the finished drug product. The control methods are validated according to international guidelines. Batch data show consistent quality of the drug product.
- The drug product is packaged in (Aluminium-OPA/Alu/PVC blister, each containing 60 tablets, each containing 12 tablets/blister).
- Appropriate stability data have been generated in the packaging material intended for commercial use and following relevant international guidelines. The data show good stability of the finished product and support the shelf life

There are no issues pertaining to drug substance and drug product stability. There are no issues pertaining to drug substance and drug product specifications. All analytical procedures are validated.

Bioequivalence Study

Bioequivalence study under fasting conditions:

Ratio and 90% Confidence Intervals (CI) of Fylibix® (Dasatinib) 140 mg Tablet versus Sprycel® (Dasatinib) 140 mg Tablet:

Pharmacokinetic Parameter	**Point Estimate**	**90% CI**
C_{max} (ng/ml)	107.01%	100.68% - 113.74%
AUC_{0-t} (ng/ml)	117.82%	111.90% - 124.06%
$AUC_{0-\infty}$ (ng/ml)	118.00%	112.37% - 123.90%

Bioequivalence study under fed conditions:

Ratio and 90% Confidence Intervals (CI) of Fylibix® (Dasatinib) 140 mg Tablet versus Sprycel® (Dasatinib) 140 mg Tablet:

Pharmacokinetic Parameter	**Point Estimate**	**90% CI**
C_{max} (ng/ml)	112.89%	105.27% - 121.07%
AUC_{0-t} (ng/ml)	109.22%	105.13% - 113.47%
$AUC_{0-\infty}$ (ng/ml)	108.98%	105.13% - 112.98%

Based on the results obtained in this study, Fylibix® (Dasatinib) 140 mg of Remedica Ltd, Cyprus is **bioequivalent** to Sprycel® (Dasatinib) 140 mg of Bristol-Myers Squibb Pharma EEIG, UK under fasting and fed Conditions.

Product Information

The approved Summary of Product Characteristics (SPC) with the submission can be found in Saudi Drug Information System (SDI) at: https://sdi.sfda.gov.sa/

The date of revision of this text corresponds to that of the Saudi PAR. New information concerning the authorized medicinal product in question will not be incorporated into the Saudi PAR. New findings that could impair the medicinal product's quality, efficacy, or safety are recorded and published at (SDI or Summary Saudi-PAR report).

For inquiry and feedback regarding Saudi PAR, please contact us at Saudi.PAR@sdfa.gov.sa